Aim: Improved results have made renal transplantation the favored option for treating patients with end stage renal disease. Although the risk of allograft rejection still remains a major concern for short-and long-term grafts survival, serum creatinine is the most successful biomarker to predict acute renal rejection. Methods: Present analysis was carried out to assess the extent of additional risk of acute renal rejection with elevated baseline serum creatinine. Data were observed from December 2009 to April 2013 on various factors on 307 patients, who underwent renal transplant at Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS, Lucknow). Follow-up data of 90 days post-transplant were analyzed. Cox Proportional Hazards model was applied to identify the determinants of graft rejection. Survival curves for various contributing factors were obtained.
Introduction
Conditions such as hypertension and diabetes mellitus that are associated with progression to end stage renal disease (ESRD) are prevalent in developing countries. 1 India, with over 1.25 billion population, observes varied spectrum of CKD due to varied ethnicity, social class, and rural-urban divide together with food habits. The most common cause of ESRD in India is diabetic nephropathy and is consistent with the worldwide trend of steady rise of diabetes contributing to ESRD. 2 Indian patients enter into ESRD at younger ages compared to developed nations, thus affecting the most bread winners of their families. Incidence of ESRD in India shows alarming annual growth rate. With an estimated ESRD of 100 per million, there could be about 100,000 patients per year. The average crude and age-adjusted incidence rates were estimated as 151 and 232 per million population, respectively. [2] [3] [4] Worldwide, the number receiving renal replacement therapy (RRT) is estimated at more than 1.4 million, whereas more than two million patients are in need of RRT. Its incidence is approximately growing by 8% annually. 5, 6 RRT is beyond the reach of a large number of CKD patients in many developing countries, including India. It is reported that <10% of all Indian ESRD patients receive any meaningful RRT (3.25 per million populations) 7 ; cost of treatment being the main reason. Most (90%) of ESRD patients cannot afford long-term RRT and die within weeks to months of diagnosis. 8, 9 Renal transplantation delivers longer survival and advantages of better quality of life over dialysis but requires major surgical intervention. Despite being cumbersome, a proper functioning renal transplant service is cost-effective. It requires concordance between nephrologists, urologists, laboratory scientists, pathologists, immunologists, and many other health specialists to ensure a successful transplant outcome. Lack of access to transplantation centers due to limited or no facilities, quality and safety issues, restricted choice of organs from living and cadaveric donors are the major obstacles faced by ESRD patients living in developing countries. In addition, lack of public awareness, education, and motivation for organ donation as well as lack of trained manpower contribute major limitation of transplant program. 1 Reported outcomes of renal transplants are not comprehensively reliable. RRT is linked with high incidence of various complications including acute graft rejections, which causes major morbidity and mortality in later stages. 1 Allograft rejection is still around 15% worldwide, though new immunosuppressive drugs have brought substantial reduction in early graft rejection. 10 Significant improvement in patient survival over the last four decades has been recorded due to decreased acute rejection (AR) and infections; the risk of allograft rejection in patients from developing nations is still a major concern. AR can occur as early as one week after transplant, extending up to months to years laterthe risk being highest in the first three months. It occurs in roughly 10-20% of kidney transplants. 11 Kidney transplant patients may not have proper renal function and have elevated creatinine level due to either parenchymal diseases or organ rejection or various infections. Understanding of factors influencing early acute rejection is very important. There are few systematic studies on acute rejection to understand its process and determinants. The present analysis is aimed to assess the pattern and risk of acute rejection during early transplant period.
Methods
Data from 307 kidney transplant recipients treated at a tertiary care center, during December 2009 to April 2013 were included in the study. Since this study does not involve live human participants and is based on data derived from them during routine patient care, the ethical review was exempted under clause 5.3 (ii) of SOP for ethical reviews at our institution, which has been approved and adopted as per Helsinki Guidelines. Age, gender, vascular access, immunosuppressant, donor relationship with the recipient, baseline serum creatinine level, blood group, and HLA matching of patient and donor were considered for analysis. Some of the variables were converted into categories for appropriate clinical interpretation. The age was divided into 3 categories, e.g. <30 years, 30-50 years and ≥50 years. Donors were classified as blood relatives and non-blood relatives. Vascular access is clubbed into two categories: first of those on arterio-venous fistula (AVF) and the second other than AVF. Blood group was divided as matching and non-matching, further ABO compatible or non-compatible. HLA matching was classified in three categories: 0-1, 2-3 and 4-6 out of 6. Serum creatinine level (mg/dl) was divided in 3 groups: <1.10, 1.10-1.50 and ≥1.50. Early acute rejection was identified based on graft biopsy. The effect of each variable on duration of early acute rejection was examined separately using Kaplan-Meier method. The variables found significant in univariate analysis were included in Cox Proportional Hazard model for multivariate analysis. Hazard ratio, regression coefficient, exp (b), and its 95% confidence interval were computed for each significant predictor. The survival function at mean level of each covariate was also computed.
Results
General profile of transplant cases according to status of early acute graft rejection is presented in (CsA) was given in 6.2% cases. The baseline serum creatinine level of around one third (32.2%) cases was <1.10 mg/dl, while 56.7% patients had baseline serum creatinine between 1.10 and 1.50 mg/dl and remaining 11.1%, ≥1.50 mg/dl. Mann-Whitney test indicated that creatinine levels in cases with early graft rejection were higher than in cases with no rejection (Table 1 ). About 61.2% cases had uneventful postoperative recovery, whereas 11.7% patients suffered from infections, 16.4% had surgical complications and the remaining 5.2% had calcineurin-inhibitor (CNI) toxicity ( Table 2) . Biopsy proven acute rejections after discharge were 5.5%, out of which 35.3% acute rejections occurred within 15 days, 29.4% between 15 and 30 days, and rest 35.3% after a month from discharge. Baseline serum creatinine level and type of immunosuppressant were significantly different for cases of early rejection and no rejection. Rest of the variables had no any significant difference over these two groups (Table 1) . Kaplan-Meier survival curves for different types of baseline serum creatinine categories and immunosuppressants used are given in Fig. 1 . The rejection rate among those receiving cyclosporine was 15.79% compared to 4.86% in those receiving tacrolimus. Similarly, higher was the baseline serum creatinine level at 2-week post-transplant, higher was the risk of acute rejection ( p < 0.001). The percentages of risk of acute rejection among cases with baseline serum creatinine level <1.10 mg/dl, between 1.10 and 1.50 mg/dl and ≥1.50 mg/dl were 2.02%, 3.44% and 26.47%, respectively. Fig. 1 indicates poor survival of transplanted allograft among cases receiving cyclosporine and with baseline creatinine level ≥1.50 mg/dl. Proportion of recipients with baseline serum creatinine level ≥1.50 mg/dl, whose allograft was surviving for one month, was 76%, whereas above 98% allograft were surviving at one month in patients with creatinine <1.50 mg/dl. 96% allograft survived at two months, who received tacrolimus regime of immunosuppressant, whereas those given cyclosporine just had 84% allograft surviving at two months. The Cox PH model results combined for immunosuppressant and creatinine levels are presented in Table 3 . The hazard of acute rejection was about 4 times higher (HR = 3.83, CI: 1.10-13.33) in those cases receiving cyclosporine than those on tacrolimus. Compared to the transplant cases with i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 9 0 -9 4 baseline serum creatinine <1.10 mg/dl, the risk of AR among those with creatinine level ≥1.50 mg/dl was about 16 times higher (HR = 16.01, CI: 3.45-74.29), while almost similar in those with creatinine between 1.10 and 1.50 mg/dl (HR = 1.73, CI: 0.35-8.55). The cumulative survival curve (Fig. 2) indicated steep fall of survival during first 20 days and after 65 days. Allograft survival was almost similar in cases with baseline serum creatinine <1.50 mg/dl irrespective of two categories (below 1.10 and between 1.10 and 1.50). Post-transplant survival of allograft continues to decrease at slower rate and remains above 90% at 90 days. The proportion of cases, whose allograft was surviving at one month was 97% (Fig. 2 ).
Discussion
Acute rejection being one of the complications of allograft dysfunction is still a major concern after kidney transplantation, though newer immunosuppressive has reduced its incidence. 12 Acute rejection manifests as an increase in serum creatinine and less often, with haematuria, graft tenderness and fever. The short-term graft survival after treatment of AR has improved; however, the long-term outcome is not i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 9 0 -9 4
promising and AR remains a major factor for chronic allograft dysfunction. 13, 14 Donor age, donor-recipient human leukocyte antibody mismatch, Panel Reactive Antibodies (PRA), ethnicity, and delayed graft function have been shown to be associated with the risk of graft rejection. 15 The function of graft can deteriorate at any time post-transplant. However, the risks and mechanisms may vary at different times. The acute rejection of allograft concerns to both developed and developing nations. Data indicate that in total, 10.2% allograft are rejected within 90 days of transplant. Almost half of them (5.5%) are rejected after discharge. Such rejections pose mental trauma and great economic loss to the recipients particularly from nations with poor per capita income. The elevated serum creatinine level is the indicator of AR; though baseline (predischarge) serum creatinine level ≥1.50 mg/dl was only in 11.1% of the cases.
The immunosuppressant' and the baseline creatinine emerged as the risk factors to early acute rejection. The allograft survival function presented in Fig. 1 indicates that risk of early rejection was similar in the patients having baseline serum creatinine below 1.10 mg/dl and between 1.10 and 1.50 mg/dl. The risk of rejection in a group of patients with baseline serum creatinine ≥1.50 mg/dl was 16 times higher. Acute rejection after 3 months post-transplant is uncommon; unless compliance to immunosuppressive therapy is poor. 16 The use of tacrolimus, as an alternative to cyclosporine, has increased in recent years. 17 Tacrolimus has proved to be a more effective drug resulting in significant reduction of biopsy confirmed acute rejection episodes compared with cyclosporine ( p < 0.01). Similar results were found in living and cadaveric renal allograft recipient's. 1, 18, 19 Transplant cases with elevated baseline serum creatinine levels at two weeks post-transplant and those on cyclosporine based immunosuppressant are at higher risk of acute rejection and would require more frequent follow-up and monitoring to diagnose early acute rejection episodes.
